BioAtla’s (BCAB) “Market Outperform” Rating Reaffirmed at JMP Securities

BioAtla (NASDAQ:BCAB)‘s stock had its “market outperform” rating reiterated by JMP Securities in a research note issued on Monday, Benzinga reports. They presently have a $5.00 price target on the stock. JMP Securities’ price objective would indicate a potential upside of 187.36% from the company’s previous close.

BioAtla Trading Down 3.9 %

Shares of BCAB traded down $0.07 during midday trading on Monday, hitting $1.74. The stock had a trading volume of 78,717 shares, compared to its average volume of 715,243. The business has a 50-day simple moving average of $1.70 and a two-hundred day simple moving average of $2.15. The firm has a market cap of $83.72 million, a P/E ratio of -0.70 and a beta of 1.06. BioAtla has a fifty-two week low of $1.14 and a fifty-two week high of $4.02.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. During the same quarter in the previous year, the company earned ($0.75) EPS. On average, analysts expect that BioAtla will post -1.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAtla

A number of institutional investors have recently added to or reduced their stakes in BCAB. Price T Rowe Associates Inc. MD bought a new stake in BioAtla in the first quarter valued at about $45,000. Ground Swell Capital LLC acquired a new stake in shares of BioAtla in the second quarter valued at $33,000. Valmark Advisers Inc. bought a new position in shares of BioAtla in the second quarter worth about $34,000. Rinkey Investments bought a new position in BioAtla in the 2nd quarter worth approximately $35,000. Finally, Virtu Financial LLC acquired a new position in shares of BioAtla during the first quarter valued at $103,000. 77.23% of the stock is owned by institutional investors and hedge funds.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.